S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Bank failures and rescue test Yellen's decades of experience
Germany, EU reach agreement in combustion engine row
"Prepare for Five Years of Famine" (Ad)
Intel co-founder, philanthropist Gordon Moore dies at 94
'What can we do?': Millions in African countries need power
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Judge rules online archive's book service violated copyright
Renamed Horseshoe to host Poker World Series on Vegas Strip
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Bank failures and rescue test Yellen's decades of experience
Germany, EU reach agreement in combustion engine row
"Prepare for Five Years of Famine" (Ad)
Intel co-founder, philanthropist Gordon Moore dies at 94
'What can we do?': Millions in African countries need power
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Judge rules online archive's book service violated copyright
Renamed Horseshoe to host Poker World Series on Vegas Strip
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Bank failures and rescue test Yellen's decades of experience
Germany, EU reach agreement in combustion engine row
"Prepare for Five Years of Famine" (Ad)
Intel co-founder, philanthropist Gordon Moore dies at 94
'What can we do?': Millions in African countries need power
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Judge rules online archive's book service violated copyright
Renamed Horseshoe to host Poker World Series on Vegas Strip
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Bank failures and rescue test Yellen's decades of experience
Germany, EU reach agreement in combustion engine row
"Prepare for Five Years of Famine" (Ad)
Intel co-founder, philanthropist Gordon Moore dies at 94
'What can we do?': Millions in African countries need power
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Judge rules online archive's book service violated copyright
Renamed Horseshoe to host Poker World Series on Vegas Strip
NASDAQ:SAGE

Sage Therapeutics - SAGE Stock Forecast, Price & News

$42.91
+0.46 (+1.08%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$41.51
$43.04
50-Day Range
$39.56
$46.57
52-Week Range
$27.36
$49.56
Volume
306,346 shs
Average Volume
589,128 shs
Market Capitalization
$2.56 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$51.14

Sage Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.31 Rating Score
Upside/​Downside
19.2% Upside
$51.14 Price Target
Short Interest
Bearish
10.15% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.37
Upright™ Environmental Score
News Sentiment
1.06mentions of Sage Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$519,394 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($8.11) to ($7.56) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.17 out of 5 stars

Medical Sector

386th out of 989 stocks

Pharmaceutical Preparations Industry

175th out of 480 stocks


SAGE stock logo

About Sage Therapeutics (NASDAQ:SAGE) Stock

SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel medicines. It targets diseases and disorders of the brain with three key focus areas: depression, neurology, and neuropsychiatry. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010, and is headquartered in Cambridge, MA.

Receive SAGE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sage Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SAGE Stock News Headlines

Essential Tremor Treatment Market Size by 2031
Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
Banking Nightmare
During and after the Great Financial Crisis of 2008, 485 U.S. banks went under. Here at Weiss Ratings, we warned about 484 — an accuracy rate of 99.8%. Now, we have a new warning. But this time, it's not just about a few hundred banks … it's about nearly every single bank in America …
Sage Therapeutics: FDA To Review NDA For Zuranolone - Quick Facts
See More Headlines
Receive SAGE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sage Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SAGE Company Calendar

Last Earnings
2/16/2023
Today
3/25/2023
Next Earnings (Estimated)
5/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SAGE
Employees
471
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$51.14
High Stock Price Forecast
$73.00
Low Stock Price Forecast
$37.00
Forecasted Upside/Downside
+19.2%
Consensus Rating
Hold
Rating Score (0-4)
2.31
Research Coverage
13 Analysts

Profitability

Net Income
$-532,780,000.00
Net Margins
-6,930.97%
Pretax Margin
-6,931.88%

Debt

Sales & Book Value

Annual Sales
$7.69 million
Book Value
$21.05 per share

Miscellaneous

Free Float
56,852,000
Market Cap
$2.56 billion
Optionable
Optionable
Beta
1.15

Key Executives

  • Barry E. GreeneBarry E. Greene
    President, Chief Executive Officer & Director
  • Kimi E. Iguchi
    Chief Financial & Accounting Officer
  • Al Robichaud
    Chief Scientific Officer
  • Amy Schacterle
    Senior VP-Research & Development Strategy
  • Matt Lasmanis
    Chief Technology & Innovation Officer













SAGE Stock - Frequently Asked Questions

Should I buy or sell Sage Therapeutics stock right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sage Therapeutics in the last twelve months. There are currently 9 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" SAGE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SAGE, but not buy additional shares or sell existing shares.
View SAGE analyst ratings
or view top-rated stocks.

What is Sage Therapeutics' stock price forecast for 2023?

13 brokerages have issued 12 month price objectives for Sage Therapeutics' shares. Their SAGE share price forecasts range from $37.00 to $73.00. On average, they predict the company's share price to reach $51.14 in the next year. This suggests a possible upside of 19.2% from the stock's current price.
View analysts price targets for SAGE
or view top-rated stocks among Wall Street analysts.

How have SAGE shares performed in 2023?

Sage Therapeutics' stock was trading at $38.14 at the start of the year. Since then, SAGE shares have increased by 12.5% and is now trading at $42.91.
View the best growth stocks for 2023 here
.

When is Sage Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023.
View our SAGE earnings forecast
.

How were Sage Therapeutics' earnings last quarter?

Sage Therapeutics, Inc. (NASDAQ:SAGE) released its quarterly earnings results on Thursday, February, 16th. The biopharmaceutical company reported ($2.47) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.37) by $0.10. The biopharmaceutical company had revenue of $2.87 million for the quarter, compared to the consensus estimate of $1.94 million. Sage Therapeutics had a negative trailing twelve-month return on equity of 37.03% and a negative net margin of 6,930.97%. The firm's revenue was up 74.7% on a year-over-year basis. During the same period last year, the firm earned ($2.12) EPS.

What other stocks do shareholders of Sage Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sage Therapeutics investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Netflix (NFLX), Roku (ROKU), QUALCOMM (QCOM) and Bristol-Myers Squibb (BMY).

What is Sage Therapeutics' stock symbol?

Sage Therapeutics trades on the NASDAQ under the ticker symbol "SAGE."

Who are Sage Therapeutics' major shareholders?

Sage Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (3.19%), JPMorgan Chase & Co. (2.37%), Dimensional Fund Advisors LP (2.22%), Geode Capital Management LLC (1.69%), Marshall Wace LLP (1.57%) and The Manufacturers Life Insurance Company (1.05%). Insiders that own company stock include Barry E Greene, Barry E Greene, George Golumbeski, James M Frates and Jeffrey M Jonas.
View institutional ownership trends
.

How do I buy shares of Sage Therapeutics?

Shares of SAGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sage Therapeutics' stock price today?

One share of SAGE stock can currently be purchased for approximately $42.91.

How much money does Sage Therapeutics make?

Sage Therapeutics (NASDAQ:SAGE) has a market capitalization of $2.56 billion and generates $7.69 million in revenue each year. The biopharmaceutical company earns $-532,780,000.00 in net income (profit) each year or ($8.98) on an earnings per share basis.

How many employees does Sage Therapeutics have?

The company employs 471 workers across the globe.

How can I contact Sage Therapeutics?

Sage Therapeutics' mailing address is 215 FIRST STREET, CAMBRIDGE MA, 02142. The official website for the company is www.sagerx.com. The biopharmaceutical company can be reached via phone at (617) 299-8380, via email at ir@sagerx.com, or via fax at 617-299-8379.

This page (NASDAQ:SAGE) was last updated on 3/25/2023 by MarketBeat.com Staff